Silence Therapeutics PLC
NASDAQ:SLN

Watchlist Manager
Silence Therapeutics PLC Logo
Silence Therapeutics PLC
NASDAQ:SLN
Watchlist
Price: 5.82 USD 2.46% Market Closed
Market Cap: $271.6m

Operating Margin

-1 449.9%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 449.9%
=
Operating Income
£-27.2m
/
Revenue
£1.4m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 449.9%
=
Operating Income
$-27.2m
/
Revenue
£1.4m

Peer Comparison

Country Company Market Cap Operating
Margin
UK
Silence Therapeutics PLC
OTC:SLNCF
346.6m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 99% of companies in United Kingdom
Percentile
1st
Based on 3 579 companies
1st percentile
-1 449.9%
Low
-195 650% — 0%
Typical Range
0% — 0.2%
High
0.2% — 4 630.7%
Distribution Statistics
United Kingdom
Min -195 650%
30th Percentile 0%
Median 0.1%
70th Percentile 0.2%
Max 4 630.7%

Silence Therapeutics PLC
Glance View

Market Cap
271.6m USD
Industry
Biotechnology

Silence Therapeutics Plc engages in the discovery, delivery and development of ribonucleic acid (RNA) therapeutics. The firm is focused on discovering and developing molecules combining short interfering ribonucleic acid (siRNA), to inhibit the expression of target genes in the pathology of diseases with unmet medical need. Its siRNA molecules are designed to harness the body’s natural mechanism of RNA interference (RNAi), by specifically binding to and degrading messenger RNA, or mRNA, molecules that encode specific targeted disease-associated proteins in a cell. The Company’s mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform is a platform of precision-engineered medicines designed to target for specific disease-associated genes in the liver. The Company’s clinical development programs include SLN360, for the prevalent unmet need in reducing cardiovascular risk in people born with Lipoprotein(a), or Lp(a), levels and SLN124, for rare iron loading anemia conditions, including thalassemia and myelodysplastic syndrome (MDS).

SLN Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-1 449.9%
=
Operating Income
£-27.2m
/
Revenue
£1.4m
How has Operating Margin changed over time?

Over the last 7 months, Silence Therapeutics PLC’s Operating Margin has increased from -7 020.5% to -1 449.9%. During this period, it reached a low of -7 020.5% on Dec 1, 2019 and a high of -1 578.9% on Jul 30, 2020.

Back to Top